In India, over 50,000 patients are diagnosed with early breast cancer (EBC) every year.
Breast cancer is the cancer which is most prevalent amongst women in India. It significantly impacts the quality of life of survivors and their families, who live with the fear of recurrence.
“The approval of Ramiven for treatment of EBC brings more optimism by providing a new treatment option to the healthcare professionals for their patients,” Eli Lilly and Company – India & India Subcontinent Managing Director Vineet Gupta said in a statement.